New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.
New Oncology has entered into a research agreement with Gustave Roussy Cancer Campus in Paris.
Under this agreement, New Oncology will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows sample processing compatible with both daily clinical routine and standard sample material, i.e. FFPE (formalin-fixed, paraffin-embedded) tissue, according to the company.
Gustave Roussy is an international institute in oncology with a staff of 2,600 health professionals. By devoting 20% of its budget to research, it aims to promote research as an innovative engine for the benefit of patients. Gustave Roussy is a private health facility working within the French public health system and is authorized to receive donations and bequests.
“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Prof. Jean-Charles Soria, Head of the Drug Development Department at Gustave Roussy Cancer Campus.
“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology center. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients” commented Andreas Jenne, PhD, CEO of New Oncology, the molecular diagnostics division of Blackfield AG, a company specializing in cancer genome analysis.
New Oncology’s proprietary diagnostic platform ‘NEO’ enables physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. Its pan-cancer diagnostic test NEOplus detects actionable genetic alterations with short turn-around times and identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample, according to the vendor. It works with a tumor board comprising renowned cancer experts, facilitating translation of the latest findings in targeted therapy into optimized patient care.
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.